BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 29273856)

  • 21. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
    Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
    JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.
    Munkhaugen J; Sverre E; Otterstad JE; Peersen K; Gjertsen E; Perk J; Gullestad L; Moum T; Dammen T; Husebye E
    Eur J Prev Cardiol; 2017 Jun; 24(9):981-989. PubMed ID: 28196429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LDL-cholesterol change and goal attainment following statin intensity titration among Asians in primary care: a retrospective cohort study.
    Fang HSA; Gao Q; Lee ML; Hsu W; Tan NC
    Lipids Health Dis; 2021 Jan; 20(1):2. PubMed ID: 33407522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.
    Simpson RJ; Tunceli K; Ramey DR; Neff DR; Kern DM; Hsieh HM; Wertz DA; Stephenson JJ; Marrett E; Tomassini JE; Jacobson TA
    J Clin Lipidol; 2013; 7(5):399-407. PubMed ID: 24079280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
    Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
    Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The need for a systematic approach to statin switching: an analysis of real-world experience.
    Kakavas PW; McManus JL; Wolfe TA; Guidry T; Flores DN; Ter Riet LB; Glover JJ; Sell H
    J Cardiovasc Nurs; 2013; 28(6):565-72. PubMed ID: 23064180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
    Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
    Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial.
    Newman JD; Alexander KP; Gu X; O'Brien SM; Boden WE; Govindan SC; Senior R; Moorthy N; Rezende PC; Demkow M; Lopez-Sendon JL; Bockeria O; Pandit N; Gosselin G; Stone PH; Spertus JA; Stone GW; Fleg JL; Hochman JS; Maron DJ
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006002. PubMed ID: 31718297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
    Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.
    Teramoto T; Uno K; Miyoshi I; Khan I; Gorcyca K; Sanchez RJ; Yoshida S; Mawatari K; Masaki T; Arai H; Yamashita S
    Atherosclerosis; 2016 Aug; 251():248-254. PubMed ID: 27419905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade?
    Vodonos A; Ostapenko I; Toledano R; Henkin Y; Zahger D; Wolak T; Sherf M; Novack V
    Eur J Intern Med; 2015 May; 26(4):268-72. PubMed ID: 25770073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk Factors Associated with Failure to Achieve the Low Density Lipoprotein Cholesterol Therapeutic Target in Patients with Acute Coronary Syndrome: A Longitudinal, Single Centre Investigation.
    Hajahmadi Pourrafsanjani M; Khayati Shal E; Khezrpour S
    High Blood Press Cardiovasc Prev; 2019 Feb; 26(1):37-43. PubMed ID: 30684247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men.
    Moreno-Arellano S; Delgado-de-Mendoza J; Santi-Cano MJ
    Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):810-815. PubMed ID: 29754716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease.
    Lee JH; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    J Vasc Surg; 2016 Mar; 63(3):756-63. PubMed ID: 26603545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.
    Laufs U; Karmann B; Pittrow D
    Clin Res Cardiol; 2016 Sep; 105(9):783-90. PubMed ID: 27120330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.